Cargando…
Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release
AIM: To investigate methods for identifying specific cyclophilin D (CypD) inhibitors derived from quinoxaline, thus developing possible lead compounds to inhibit mitochondrial permeability transition (MPT) pore opening. METHODS: Kinetic analysis of the CypD/inhibitor interaction was quantitatively p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091716/ https://www.ncbi.nlm.nih.gov/pubmed/16174436 http://dx.doi.org/10.1111/j.1745-7254.2005.00189.x |
_version_ | 1783510051776888832 |
---|---|
author | Guo, Hong-xia Wang, Feng Yu, Kun-qian Chen, Jing Bai, Dong-lu Chen, Kai-xian Shen, Xu Jiang, Hua-liang |
author_facet | Guo, Hong-xia Wang, Feng Yu, Kun-qian Chen, Jing Bai, Dong-lu Chen, Kai-xian Shen, Xu Jiang, Hua-liang |
author_sort | Guo, Hong-xia |
collection | PubMed |
description | AIM: To investigate methods for identifying specific cyclophilin D (CypD) inhibitors derived from quinoxaline, thus developing possible lead compounds to inhibit mitochondrial permeability transition (MPT) pore opening. METHODS: Kinetic analysis of the CypD/inhibitor interaction was quantitatively performed by using surface plasmon resonance (SPR) and fluorescence titration (FT) techniques. IC(50) values of these inhibitors were determined by PPIase inhibition activity assays. RESULTS: All the equilibrium dissociation constants (K(D)) of the seven compounds binding to CypD were below 10 μmol/L. The IC(50) values were all consistent with the SPR and FT results. Compounds GW2, 5, 6, and 7 had high inhibition activities against Ca(2+)-dependent rat liver mitochondrial swelling and Ca(2+) uptake/release. Compound GW5 had binding selectivity for CypD over CypA. CONCLUSION: The agreement between the measured IC(50) values and the results of SPR and FT suggests that these methods are appropriate and powerful methods for identifying CypD inhibitors. The compounds we screened using these methods (GW1-7) are reasonable CypD inhibitors. Its potent ability to inhibit mitochondrial swelling and the binding selectivity of GW5 indicates that GW5 could potentially be used for inhibiting MPT pore opening. |
format | Online Article Text |
id | pubmed-7091716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70917162020-03-24 Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release Guo, Hong-xia Wang, Feng Yu, Kun-qian Chen, Jing Bai, Dong-lu Chen, Kai-xian Shen, Xu Jiang, Hua-liang Acta Pharmacol Sin Article AIM: To investigate methods for identifying specific cyclophilin D (CypD) inhibitors derived from quinoxaline, thus developing possible lead compounds to inhibit mitochondrial permeability transition (MPT) pore opening. METHODS: Kinetic analysis of the CypD/inhibitor interaction was quantitatively performed by using surface plasmon resonance (SPR) and fluorescence titration (FT) techniques. IC(50) values of these inhibitors were determined by PPIase inhibition activity assays. RESULTS: All the equilibrium dissociation constants (K(D)) of the seven compounds binding to CypD were below 10 μmol/L. The IC(50) values were all consistent with the SPR and FT results. Compounds GW2, 5, 6, and 7 had high inhibition activities against Ca(2+)-dependent rat liver mitochondrial swelling and Ca(2+) uptake/release. Compound GW5 had binding selectivity for CypD over CypA. CONCLUSION: The agreement between the measured IC(50) values and the results of SPR and FT suggests that these methods are appropriate and powerful methods for identifying CypD inhibitors. The compounds we screened using these methods (GW1-7) are reasonable CypD inhibitors. Its potent ability to inhibit mitochondrial swelling and the binding selectivity of GW5 indicates that GW5 could potentially be used for inhibiting MPT pore opening. Nature Publishing Group UK 2005-10 /pmc/articles/PMC7091716/ /pubmed/16174436 http://dx.doi.org/10.1111/j.1745-7254.2005.00189.x Text en © CPS and SIMM 2005 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Guo, Hong-xia Wang, Feng Yu, Kun-qian Chen, Jing Bai, Dong-lu Chen, Kai-xian Shen, Xu Jiang, Hua-liang Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release |
title | Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release |
title_full | Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release |
title_fullStr | Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release |
title_full_unstemmed | Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release |
title_short | Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca(2+) uptake/release |
title_sort | novel cyclophilin d inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and ca(2+) uptake/release |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091716/ https://www.ncbi.nlm.nih.gov/pubmed/16174436 http://dx.doi.org/10.1111/j.1745-7254.2005.00189.x |
work_keys_str_mv | AT guohongxia novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease AT wangfeng novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease AT yukunqian novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease AT chenjing novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease AT baidonglu novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease AT chenkaixian novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease AT shenxu novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease AT jianghualiang novelcyclophilindinhibitorsderivedfromquinoxalineexhibithighlyinhibitoryactivityagainstratmitochondrialswellingandca2uptakerelease |